ReviewPharmacoEconomics2016
Cost-of-Illness Studies: An Updated Review of Current Methods.
Review in PharmacoEconomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Cost-of-Illness of Skin Cancer: A Systematic Review.PharmacoEconomics · 2024Pooled it
- Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.PharmacoEconomics · 2021Pooled it
- Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review.PharmacoEconomics · 2020Pooled it
- Clinical and economic outcomes evaluated in Lyme disease: a systematic review.Parasites & vectors · 2020Pooled it
- Cost-of-illness studies in nine Central and Eastern European countries.The European journal of health economics : HEPAC : health economics in prevention and care · 2019Pooled it
- Costs of Invasive Meningococcal Disease: A Global Systematic Review.PharmacoEconomics · 2018Pooled it
- Trial
- GP- and practice-related variation in ambulatory sensitive hospitalisations of older primary care patients.BMC family practice · 2020Trial
- The economic burden of neurological disorders in Europe - COIN-Eu: Study design and analytic framework.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- What's Needed for a Migraine Cost-Of-Illness Study in Aotearoa New Zealand: Review of Data Sources and Gaps.Journal of the Royal Society of New Zealand · 2026Review
- Cost analysis of transthyretin amyloid cardiomyopathy in heart failure patients with preserved ejection fraction in Spain.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Opening the Discussion on the Costs of Pedophilic Disorder as a Mental Health Concern.Archives of sexual behavior · 2026Article
- The economic burden of maternal mortality: a scoping review.Health economics review · 2026Review
- Burden of hypertension-related diseases in Eastern Mediterranean region.Journal of Taibah University Medical Sciences · 2026Article
- Article
- The Economic Cost of Obesity: A Cost-of-Illness Study in Greece.Applied health economics and health policy · 2026Article
- Model-Based Economic Analyses of Haemophilia from a Societal Perspective: A Scoping Review.PharmacoEconomics - open · 2026Review
- Estimating the economic and societal burden of suicide and suicide attempts in India: a study protocol.BMJ open · 2025Article
- Drivers of hospital costs in ANCA-associated vasculitis patients with long-term follow-up-a real-world cost analysis.Clinical kidney journal · 2025Article
- Instrumental variables in the cost of illness featuring type 2 diabetes.Health services research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCost-of-illness (COI) studies provide policy-relevant information for cross-country, longitudinal, and other cost comparisons. Prior studies have called for standardization in COI methods. We investigated trends, identified factors associated with variation in COI estimation methods, and characterized reporting of heterogeneity in COI estimates.
methodsThe review of COI studies was implemented following (i) a structured search of PubMed, SCOPUS and EMBASE; (ii) a review of abstracts; (iii) a full-text review; and (iv) classification of articles according to six COI estimation methods: Sum_All Medical, Sum_Diagnosis Specific, Matched, Regression, Other_Total and Other_Incremental. Descriptive and multivariable regression analyses were conducted.
resultsOf the 993 studies included in the full-text review, 186 (18.7 %) were Sum_All Medical, 458 (46.1 %) were Sum_Diagnosis Specific, 96 (9.7 %) were Matched, 97 (9.8 %) were Regression, 70 (7.1 %) were Other_Incremental, and 68 (6.9 %) were Other_Total. Compared with the early period, publications in the middle and late period were associated with lower odds of using Sum_All Medical compared with Sum_Diagnosis Specific (adjusted odds ratio [AOR]middle 0.14; 95 % CI 0.07-0.28; AORlate 0.44; 95 % CI 0.29-0.67). Overall, 640 articles (64 %) reported COI estimates across patient groups defined by patient-level factors, while 247 articles (25 %) reported COI estimates across patient groups defined by non-patient-level factors.
conclusionThe disease-specific total costing method (Sum_Diagnosis Specific) was most commonly used and its use increased over the time period covered by this review. The investigation of subgroup heterogeneity in COI estimates represents an area for future research.
Indexed as
Identifiers
26385101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.